Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation

References

• Mayer R J, Davis R B, Schiffer C A, Berg D T, Powell B L, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Cassileth P A, Harrington D P, Appelbaum F R, Lazarus H M, Rowe J M, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Eng J Med 1998; 339: 1649–1656
   PubMed Web of Science ®Google Scholar
• Dinsmore R, Kirkpatrick D, Flomenberg N, Gulati S, Kapoor N, Brochstein J, et al. Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. Blood 1984; 63: 649–656
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg H J, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporin alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 31: 729–735
   Web of Science ®Google Scholar
• Koh L P, Kurup A, Goh Y T, Fook-Chong S M, Tan P H. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002; 71: 260–267
   PubMed Web of Science ®Google Scholar
• Koh L P, Tan K W, Chow H, Kurup A, Tan B H, Hwang W Y, et al. Randomised trial of itraconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Blood 2003; 102: 974a
   Web of Science ®Google Scholar
• Cheson B D, Cassileth P A, Head D R, Schiffer C A, Bennett J M, Bloomfield C D, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813–819
   PubMed Web of Science ®Google Scholar
• Blazar B R, Orr H T, Arthur D C, Kersey J H, Fillipovich A H. Restriction fragment length polymorphism as markers of engraftment in allogeneic marrow transplantation. Blood 1985; 66: 1436–1444
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, Klingemann H G, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828
   PubMed Web of Science ®Google Scholar
• Sullivan K M, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259
   PubMed Web of Science ®Google Scholar
• Sullivan K M. Graft-versus-host disease. Hematopoietic Cell Transplantation2nd edn., E D Thomas, K G Blume, S J Forman. Blackwell Science, Boston, MA 1999; 515–536
   Google Scholar
• Klein J P, Rizzo J D, Zhang M J, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001; 28: 909–915
   PubMed Web of Science ®Google Scholar
• Klein J P, Rizzo J D, Zhang M J, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: regression modeling. Bone Marrow Transplant 2001; 28: 1001–1011
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
   PubMedGoogle Scholar
• Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1991; 7: 9–12
   PubMed Web of Science ®Google Scholar
• Burnett A K, Wheatley A H, Goldstone R F, Stevens R F, Hann I M, Rees J H, , for the Medical Research Council Adult and Paediatric Working Parties, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385–400
   PubMed Web of Science ®Google Scholar
• Keating S, de Whitte T, Suciu S, Willemze R, Hayat M, Labar B, et al. The influence of HLA matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8 A study of the EORTC Leukaemia Cooperative Group and GIMEMA. Br J Haematol 1998; 102: 1344–1353
   PubMed Web of Science ®Google Scholar
• Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 45 years with acute myeloid leukemia in first complete remission: in intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003; 102: 1232–1240
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered in to MRC AML 10 Trial. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• Slovak M L, Kopecky K J, Cassileth P A, Harrington D H, Theil K S, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083
   PubMed Web of Science ®Google Scholar
• Feinstein L C, Sandmaier B M, Hegenbart U, McSweeney P A, Maloney D G, Gooley T A, et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 2003; 120: 281–288
   PubMed Web of Science ®Google Scholar
• Hegenbart U, Niederwieser D, Sandmaier B M, Maris M B, Shizuru J A, Greinix H, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444–453
   PubMed Web of Science ®Google Scholar
• Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D, et al. The role of reduced intensity conditioning allogeneic stem cell transplantation. in patients with acute myeloid leukemia: a donor versus no donor comparison. Leukemia 2005; 19: 916–920
   PubMed Web of Science ®Google Scholar
• Sayer H G, Kroger M, Beyer J, Kiehl M, Klein S A, Schaefer-Eckart K, et al. Cooperative German Transplant Study Group. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31: 1089–1095
   PubMed Web of Science ®Google Scholar
• Russell J A, Tran H T, Quinlan D, Chaudhry A, Duggan P, Brown C, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468–476
   PubMed Web of Science ®Google Scholar
• de Lima M, Couriel D, Thall P F, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857–864
   PubMed Web of Science ®Google Scholar